Skip to main content

Dr. Parks is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Parks' full profile

Already have an account?

  • Office

    14131 Midway Rd
    Suite 620
    Addison, TX 75001
    Phone+1 972-249-0200
    Fax+1 972-249-0206

Education & Training

  • University of Illinois College of Medicine at Chicago
    University of Illinois College of Medicine at ChicagoResidency, Physical Medicine and Rehabilitation, 1989 - 1992
  • Medical College of Wisconsin Affiliated Hospitals
    Medical College of Wisconsin Affiliated HospitalsResidency, Internal Medicine, 1988 - 1989
  • Medical College of Wisconsin Affiliated Hospitals
    Medical College of Wisconsin Affiliated HospitalsInternship, Transitional Year, 1987 - 1988
  • Medical College of Wisconsin
    Medical College of WisconsinClass of 1987

Certifications & Licensure

  • AZ State Medical License
    AZ State Medical License 1995 - 2026
  • CA State Medical License
    CA State Medical License 1999 - 2025
  • NV State Medical License
    NV State Medical License 1996 - 2025
  • TX State Medical License
    TX State Medical License 2013 - 2025
  • CO State Medical License
    CO State Medical License 1995 - 2015
  • NM State Medical License
    NM State Medical License 1996 - 2000
  • WI State Medical License
    WI State Medical License 1988 - 1999
  • American Board of Physical Medicine and Rehabilitation Physical Medicine & Rehabilitation
  • Join now to see all

Press Mentions

  • City of Hope and Osel Announce Exclusive License for Intellectual Property on the Use of Live Biotherapeutic Product CBM588 for Oncology Therapeutic Applications
    City of Hope and Osel Announce Exclusive License for Intellectual Property on the Use of Live Biotherapeutic Product CBM588 for Oncology Therapeutic ApplicationsJuly 14th, 2021
  • Osel Announces Positive Results from Phase 1b Trial of Live Biotherapeutic Product CBM588 in Combination with Checkpoint Inhibitor (CPI) Therapy in Metastatic Renal Cell Carcinoma
    Osel Announces Positive Results from Phase 1b Trial of Live Biotherapeutic Product CBM588 in Combination with Checkpoint Inhibitor (CPI) Therapy in Metastatic Renal Cell CarcinomaJune 7th, 2021

Professional Memberships